PURPOSE: To demonstrate the relationships among tumour location, hydronephrosis, and tumour stage in patients with Upper Urinary Tract Urothelial Carcinoma (UUT-UC). Moreover, we want to determine whether primary tumour location is an independent predictor of prognosis in those patients. METHODS: Retrospective analysis of 251 UUT-UC patients from our centre treated with radical nephroureterectomy between 2000 and 2010. Patients who had previous radical cystectomy, preoperative chemotherapy, previous contralateral UUT-UC, multifocal tumours, or metastatic disease at presentation were excluded. Overall, 217 patients were then available for evaluation. The relationships among tumour location, hydronephrosis, and tumour stage were analysed. Tumour location was categorized as renal pelvis or ureter. Progression-free survival (PFS) and cancer-specific survival (CSS) probabilities were estimated using Kaplan-Meier and Cox regression analyses. RESULTS: Tumour location was renal pelvis in 146 cases (67 %), ureter in 71 cases (33 %). Median follow-up was 52 months. Compared with renal pelvic tumours, ureteral tumours were more likely to have hydronephrosis and to be associated with advanced stages (p < 0.001), but less likely to have haematuria. The 5-year CSS estimate was 79.3 % for renal pelvic tumours and 64.7 % for ureteral tumours (p = 0.03). The 5-year PFS probability was 68.7 % for renal pelvic tumours and 54.2 % for ureteral tumours (p = 0.02). On univariable and multivariable analysis, tumour location was an independent prognostic factor for CSS (p < 0.05). CONCLUSIONS: Ureteral tumours were associated with a worse prognosis than renal pelvis tumours. The possible hypothesis may be due partially to that ureteral tumours are more likely to have hydronephrosis and less likely to have haematuria.
PURPOSE: To demonstrate the relationships among tumour location, hydronephrosis, and tumour stage in patients with Upper Urinary Tract Urothelial Carcinoma (UUT-UC). Moreover, we want to determine whether primary tumour location is an independent predictor of prognosis in those patients. METHODS: Retrospective analysis of 251 UUT-UC patients from our centre treated with radical nephroureterectomy between 2000 and 2010. Patients who had previous radical cystectomy, preoperative chemotherapy, previous contralateral UUT-UC, multifocal tumours, or metastatic disease at presentation were excluded. Overall, 217 patients were then available for evaluation. The relationships among tumour location, hydronephrosis, and tumour stage were analysed. Tumour location was categorized as renal pelvis or ureter. Progression-free survival (PFS) and cancer-specific survival (CSS) probabilities were estimated using Kaplan-Meier and Cox regression analyses. RESULTS:Tumour location was renal pelvis in 146 cases (67 %), ureter in 71 cases (33 %). Median follow-up was 52 months. Compared with renal pelvic tumours, ureteral tumours were more likely to have hydronephrosis and to be associated with advanced stages (p < 0.001), but less likely to have haematuria. The 5-year CSS estimate was 79.3 % for renal pelvic tumours and 64.7 % for ureteral tumours (p = 0.03). The 5-year PFS probability was 68.7 % for renal pelvic tumours and 54.2 % for ureteral tumours (p = 0.02). On univariable and multivariable analysis, tumour location was an independent prognostic factor for CSS (p < 0.05). CONCLUSIONS:Ureteral tumours were associated with a worse prognosis than renal pelvis tumours. The possible hypothesis may be due partially to that ureteral tumours are more likely to have hydronephrosis and less likely to have haematuria.
Authors: Giovanni Lughezzani; Maximilian Burger; Vitaly Margulis; Surena F Matin; Giacomo Novara; Morgan Roupret; Shahrokh F Shariat; Christopher G Wood; Richard Zigeuner Journal: Eur Urol Date: 2012-02-23 Impact factor: 20.096
Authors: Thomas F Chromecki; Karim Bensalah; Mesut Remzi; Grégory Verhoest; Eugene K Cha; Douglas S Scherr; Giacomo Novara; Pierre I Karakiewicz; Shahrokh F Shariat Journal: Nat Rev Urol Date: 2011-07-05 Impact factor: 14.432
Authors: Jamie C Messer; John D Terrell; Michael P Herman; Casey K Ng; Douglas S Scherr; Benjamin Scoll; Stephen A Boorjian; Robert G Uzzo; Mark Wille; Scott E Eggener; Steven M Lucas; Yair Lotan; Shahrokh F Shariat; Jay D Raman Journal: Urol Oncol Date: 2011-09-09 Impact factor: 3.498
Authors: Jay D Raman; Casey K Ng; Douglas S Scherr; Vitaly Margulis; Yair Lotan; Karim Bensalah; Jean-Jacques Patard; Eiji Kikuchi; Francesco Montorsi; Richard Zigeuner; Alon Weizer; Christian Bolenz; Theresa M Koppie; Hendrik Isbarn; Claudio Jeldres; Wareef Kabbani; Mesut Remzi; Mathias Waldert; Christopher G Wood; Marco Roscigno; Mototsuga Oya; Cord Langner; J Stuart Wolf; Philipp Ströbel; Mario Fernández; Pierre Karakiewcz; Shahrokh F Shariat Journal: Eur Urol Date: 2009-07-15 Impact factor: 20.096
Authors: Casey K Ng; Shahrokh F Shariat; Steven M Lucas; Aditya Bagrodia; Yair Lotan; Douglas S Scherr; Jay D Raman Journal: Urol Oncol Date: 2008-12-30 Impact factor: 3.498
Authors: Laura-Maria Krabbe; Aditya Bagrodia; Mary E Westerman; Bishoy A Gayed; Ahmed Q Haddad; Arthur I Sagalowsky; Shahrokh F Shariat; Payal Kapur; Yair Lotan; Vitaly Margulis Journal: World J Urol Date: 2015-05-20 Impact factor: 4.226
Authors: G Bozzini; L Nison; P Colin; A Ouzzane; D R Yates; F Audenet; G Pignot; A Arvin-Berod; O Merigot; L Guy; J Irani; F Saint; S Gardic; P Gres; F Rozet; Y Neuzillet; A Ruffion; M Roupret Journal: World J Urol Date: 2012-10-11 Impact factor: 4.226
Authors: Hwang Sung Tae; Sung Deuk Jae; Yang Kyung Sook; Sim Ki Choon; Han Na Yeon; Park Beom Jin; Kim Min Ju; Cho Sung Bum Journal: Br J Radiol Date: 2017-08-22 Impact factor: 3.039